Recruiting

isCGM & Coaching

Sponsor:

LMC Diabetes & Endocrinology Ltd.

Code:

NCT06837103

Conditions

Type 2 Diabetes

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Intermittently Scanned Continuous Glucose Monitor

Study Details

Brief summary:

The goal of this prospective study is to evaluate diabetes outcomes after initiating second generation intermittently scanned continuous glucose monitoring (isCGM) plus one pharmacist consultation session compared with capillary blood glucose (CBG) monitoring among insulin-naïve adults with type 2 diabetes (T2D) in a specialist endocrinology clinical setting in Canada.

Primary Outcome - To evaluate change in HbA1c at 3-6 months follow-up after initiating isCGM plus one pharmacist consultation (isCGM cohort) compared with CBG monitoring (CBG cohort) among insulin-naïve adults with T2D.

Secondary Outcomes - To determine the change in metabolic outcomes and patient reported outcomes (PROs) and number of non-insulin antihyperglycemic agents (AHAs) prescribed from baseline to 3-6 months (± 6 weeks) in the isCGM cohort compared to the CBG cohort. Another secondary outcome is to assess isCGM metrics and number of isCGM discontinuations in the isCGM cohort at 3-6 months (± 6 weeks) compared to baseline. Additionally the study will describe and/or evaluate glycemic and metabolic outcomes, and PROs in participants who initiate an isCGM device and opt to enroll in a diabetes coaching program (isCGM+coaching cohort) at baseline compared to follow-up at 3-6 months (± 6 weeks).

Exploratory Outcomes - To compare change in HbA1c between the matched isCGM cohort and CBG cohort by subgroups: age (< 65 years old vs ≥ 65 years old) and baseline HbA1c (< 8.5% vs ≥ 8.5%).

Conditions

Type 2 Diabetes

Study ID

NCT06837103

Start date

Apr 9, 2025

Status verified date

Apr, 2025

Completion date

May, 2026

Anticipated

Primary completion date

May, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 18 years or older
  • Clinical diagnosis of T2D ≥ one year
  • Using at least one AHA
  • Status as a Sun Life group benefits member, initiates isCGM device through Lumino Health™ Pharmacy, and completes one initial pharmacist consultation (isCGM cohort) or completes 2 or more diabetes coaching program consultations (isCGM+coaching cohort); or has private health insurance and uses CBG monitoring (CBG cohort)
  • Baseline HbA1c ≥ 7.0%
  • ≥ 1 HbA1c value up to 6 months prior to index date
  • Exclusive use of isCGM for ≥ 3 months
  • Informed consent

Exclusion Criteria:

  • Have a history of insulin use
  • Are pregnant or breastfeeding at the time of study enrollment or become pregnant during the study
  • Have an estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m2
  • Previously used rtCGM or isCGM for > 3 months
  • Recent or expectant change to antihyperglycemic medications or doses within 30 days of index date

Study Design

Enrollment

250 participants

Anticipated

Interventions and Outcome Measures

Arms

isCGM Group

Adults with T2D, who are active patients at LMC, not using insulin, and initiate a second generation isCGM device through Lumino Health™ Pharmacy, and complete one initial pharmacist consultation

CBG Group

Adults with T2D, who are active patients at LMC, not using insulin and use a CBG monitor

isCGM+Coaching Group

Adults with T2D, who are active patients at LMC, not using insulin, and initiate a second generation isCGM device through Lumino Health™ Pharmacy, and complete 2 or more diabetes coaching program consultations

Interventions

Intermittently Scanned Continuous Glucose Monitor

intervention used by the isCGM and isCGM+Coaching groups

Primary outcome measure

  • Change in HbA1c [ Time Frame: from enrollment to 3-6 month follow up ]

Central Contacts and Locations

Locations

LMC Diabetes & Endocrinology Ltd.

Recruiting

Toronto, Ontario, Canada, M4G 3E8

Contacts

Manager, Data Science

4166452929lisa.chu@lmc.ca

Research Assistant, Data Science

giovana.romero@lmc.ca

More Information

Sponsor

LMC Diabetes & Endocrinology Ltd.

Last update posted

May 4, 2025

Last verified

Apr, 2025

Keywords

  • continuous glucose monitoring
  • type 2 diabetes
  • time in range
  • HbA1c

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by LMC Diabetes & Endocrinology Ltd. on 2025-05-04.